Obesity
Conditions
Interventions
Group 1:Metformin (Taibai, 500mg*30 tablets) was purchased from Chiatai Tianqing Co., Ltd. (CFDA approval no.: Guo Yao Zhun Zi No. H20031104). Dosage and administration: 1 tablet, twice daily, taken o
Group 2:Same treatment as control group plus 300ml warm LGZL decoction (ingredients: Codonopsis pilosula, Astragalus mongholicus, Wolfiporia extensa, Atractylodes macrocephala, Ramulus Cinnamomi, Copt
Sponsors
Department of Endocrinology, Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai,China
Eligibility
Sex/Gender
All
Age
15 Years to 71 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for obesity and IR, as well as the TCM syndrome differentiation criteria for WSPD; (2) Aged 15-80 years old male and female; (3) Has given informed consent and can comply with regular follow-ups.
Exclusion criteria
Exclusion criteria: (1) Secondary obesity; (2) Acute complications, serious infections or liver and kidney dysfunction (e.g. ALT level is 2-fold above the upper limit of normal), cardiopulmonary insufficiency, alcoholism, mental illnesses, and cancer; (3) Pregnant and breastfeeding; (4) Taken weight-loss medications within the past month; (5) History of gastrointestinal bariatric surgery; (6) Clear contraindications for metformin; (7) Diabetes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM syndrome;TCM syndrome score;Body Mass Index;Waist Circumference;Homeostasis Model Assessment-Insulin Resistance Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor Necrosis Factor-a;Interleukin-2;Interleukin-6;Interleukin-10; | — |
Countries
China
Contacts
Public ContactWu Tengfei
Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine
Outcome results
None listed